Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection

Jennifer J. Kiser, Courtney V. Fletcher, Patricia M. Flynn, Coleen K. Cunningham, Craig M. Wilson, Bill G. Kapogiannis, Hanna Major-Wilson, Rolando M. Viani, Nancy X. Liu, Larry R. Muenz, D. Robert Harris, Peter L. Havens, Ana Puga, Esmine Leonard, Zulma Eysallenne, Marvin Belzer, Cathy Salata, Diane Tucker, Jaime Martinez, Kelly Bojan & 21 others Rachel Jackson, Donna C. Futterman, Elizabeth Enriquez-Bruce, Maria Campos, Linda Levin-Carmine, Mary Geiger, Angela Lee, Nehali Patel, Aditya Gaur, Mary Dillard, Ligia Peralta, Leonel Flores, Esther Collinetti, Lawrence Friedman, Donna Maturo, Bret Rudy, Mary Tanney, Adrienne DiBenedetto, Patricia Emmanuel, Silvia Callejas, Priscilla Julian

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The primary objective of this study was to measure atazanavir-ritonavir and tenofovir pharmacokinetics when the drugs were used in combination in young adults with human immunodeficiency virus (HIV). HIV-infected subjects ≥ 18 to < 25 years old receiving (≥28 days) 300/100 mg atazanavir-ritonavir plus 300 mg tenofovir disoproxil fumarate (TDF) plus one or more other nucleoside analogs underwent intensive 24-h pharmacokinetic studies following a light meal. Peripheral blood mononuclear cells were obtained at 1, 4, and 24 h postdose for quantification of intracellular tenofovir diphosphate (TFV-DP) concentrations. Twenty-two subjects were eligible for analyses. The geometric mean (95% confidence interval [CI]) atazanavir area under the concentration-time curve from 0 to 24 h (AUC0-24), maximum concentration of drug in serum (Cmax), concentration at 24 h postdose (C24), and total apparent oral clearance (CL/F) values were 35,971 ng · hr/ml (30,853 to 41,898), 3,504 ng/ml (2,978 to 4,105), 578 ng/ml (474 to 704), and 8.3 liter/hr (7.2 to 9.7), respectively. The geometric mean (95% CI) tenofovir AUC 0-24, Cmax, C24, and CL/F values were 2,762 ng · hr/ml (2,392 to 3,041), 254 ng/ml (221 to 292), 60 ng/ml (52 to 68), and 49.2 liter/hr (43.8 to 55.3), respectively. Body weight was significantly predictive of CL/F for all three drugs. For every 10-kg increase in weight, there was a 10%, 14.8%, and 6.8% increase in the atazanavir, ritonavir, and tenofovir CL/F, respectively (P ≤ 0.01). Renal function was predictive of tenofovir CL/F. For every 10 ml/min increase in creatinine clearance, there was a 4.6% increase in tenofovir CL/F (P < 0.0001). The geometric mean (95% CI) TFV-DP concentrations at 1, 4, and 24 h postdose were 96.4 (71.5 to 130), 93.3 (68 to 130), and 92.7 (70 to 123) fmol/million cells. There was an association between renal function, tenofovir AUC, and tenofovir Cmax and intracellular TFV-DP concentrations, although none of these associations reached statistical significance. In these HIV-infected young adults treated with atazanavir-ritonavir plus TDF, the atazanavir AUC was similar to those of older adults treated with the combination. Based on data for healthy volunteers, a higher tenofovir AUC may have been expected, but was not seen in these subjects. This might be due to faster tenofovir CL/F because of higher creatinine clearance in this age group. Additional studies of the exposure-response relationships of this regimen in children, adolescents, and adults would advance our knowledge of its pharmacodynamic properties.

Original languageEnglish (US)
Pages (from-to)631-637
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume52
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Tenofovir
Ritonavir
Virus Diseases
Young Adult
Pharmacokinetics
HIV
Area Under Curve
Confidence Intervals
Creatinine
Atazanavir Sulfate
Pharmaceutical Preparations
Kidney

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. / Kiser, Jennifer J.; Fletcher, Courtney V.; Flynn, Patricia M.; Cunningham, Coleen K.; Wilson, Craig M.; Kapogiannis, Bill G.; Major-Wilson, Hanna; Viani, Rolando M.; Liu, Nancy X.; Muenz, Larry R.; Harris, D. Robert; Havens, Peter L.; Puga, Ana; Leonard, Esmine; Eysallenne, Zulma; Belzer, Marvin; Salata, Cathy; Tucker, Diane; Martinez, Jaime; Bojan, Kelly; Jackson, Rachel; Futterman, Donna C.; Enriquez-Bruce, Elizabeth; Campos, Maria; Levin-Carmine, Linda; Geiger, Mary; Lee, Angela; Patel, Nehali; Gaur, Aditya; Dillard, Mary; Peralta, Ligia; Flores, Leonel; Collinetti, Esther; Friedman, Lawrence; Maturo, Donna; Rudy, Bret; Tanney, Mary; DiBenedetto, Adrienne; Emmanuel, Patricia; Callejas, Silvia; Julian, Priscilla.

In: Antimicrobial Agents and Chemotherapy, Vol. 52, No. 2, 02.2008, p. 631-637.

Research output: Contribution to journalArticle

Kiser, JJ, Fletcher, CV, Flynn, PM, Cunningham, CK, Wilson, CM, Kapogiannis, BG, Major-Wilson, H, Viani, RM, Liu, NX, Muenz, LR, Harris, DR, Havens, PL, Puga, A, Leonard, E, Eysallenne, Z, Belzer, M, Salata, C, Tucker, D, Martinez, J, Bojan, K, Jackson, R, Futterman, DC, Enriquez-Bruce, E, Campos, M, Levin-Carmine, L, Geiger, M, Lee, A, Patel, N, Gaur, A, Dillard, M, Peralta, L, Flores, L, Collinetti, E, Friedman, L, Maturo, D, Rudy, B, Tanney, M, DiBenedetto, A, Emmanuel, P, Callejas, S & Julian, P 2008, 'Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection', Antimicrobial Agents and Chemotherapy, vol. 52, no. 2, pp. 631-637. https://doi.org/10.1128/AAC.00761-07
Kiser, Jennifer J. ; Fletcher, Courtney V. ; Flynn, Patricia M. ; Cunningham, Coleen K. ; Wilson, Craig M. ; Kapogiannis, Bill G. ; Major-Wilson, Hanna ; Viani, Rolando M. ; Liu, Nancy X. ; Muenz, Larry R. ; Harris, D. Robert ; Havens, Peter L. ; Puga, Ana ; Leonard, Esmine ; Eysallenne, Zulma ; Belzer, Marvin ; Salata, Cathy ; Tucker, Diane ; Martinez, Jaime ; Bojan, Kelly ; Jackson, Rachel ; Futterman, Donna C. ; Enriquez-Bruce, Elizabeth ; Campos, Maria ; Levin-Carmine, Linda ; Geiger, Mary ; Lee, Angela ; Patel, Nehali ; Gaur, Aditya ; Dillard, Mary ; Peralta, Ligia ; Flores, Leonel ; Collinetti, Esther ; Friedman, Lawrence ; Maturo, Donna ; Rudy, Bret ; Tanney, Mary ; DiBenedetto, Adrienne ; Emmanuel, Patricia ; Callejas, Silvia ; Julian, Priscilla. / Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. In: Antimicrobial Agents and Chemotherapy. 2008 ; Vol. 52, No. 2. pp. 631-637.
@article{6a46695f34df4eaea9ffe80a83f88302,
title = "Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection",
abstract = "The primary objective of this study was to measure atazanavir-ritonavir and tenofovir pharmacokinetics when the drugs were used in combination in young adults with human immunodeficiency virus (HIV). HIV-infected subjects ≥ 18 to < 25 years old receiving (≥28 days) 300/100 mg atazanavir-ritonavir plus 300 mg tenofovir disoproxil fumarate (TDF) plus one or more other nucleoside analogs underwent intensive 24-h pharmacokinetic studies following a light meal. Peripheral blood mononuclear cells were obtained at 1, 4, and 24 h postdose for quantification of intracellular tenofovir diphosphate (TFV-DP) concentrations. Twenty-two subjects were eligible for analyses. The geometric mean (95{\%} confidence interval [CI]) atazanavir area under the concentration-time curve from 0 to 24 h (AUC0-24), maximum concentration of drug in serum (Cmax), concentration at 24 h postdose (C24), and total apparent oral clearance (CL/F) values were 35,971 ng · hr/ml (30,853 to 41,898), 3,504 ng/ml (2,978 to 4,105), 578 ng/ml (474 to 704), and 8.3 liter/hr (7.2 to 9.7), respectively. The geometric mean (95{\%} CI) tenofovir AUC 0-24, Cmax, C24, and CL/F values were 2,762 ng · hr/ml (2,392 to 3,041), 254 ng/ml (221 to 292), 60 ng/ml (52 to 68), and 49.2 liter/hr (43.8 to 55.3), respectively. Body weight was significantly predictive of CL/F for all three drugs. For every 10-kg increase in weight, there was a 10{\%}, 14.8{\%}, and 6.8{\%} increase in the atazanavir, ritonavir, and tenofovir CL/F, respectively (P ≤ 0.01). Renal function was predictive of tenofovir CL/F. For every 10 ml/min increase in creatinine clearance, there was a 4.6{\%} increase in tenofovir CL/F (P < 0.0001). The geometric mean (95{\%} CI) TFV-DP concentrations at 1, 4, and 24 h postdose were 96.4 (71.5 to 130), 93.3 (68 to 130), and 92.7 (70 to 123) fmol/million cells. There was an association between renal function, tenofovir AUC, and tenofovir Cmax and intracellular TFV-DP concentrations, although none of these associations reached statistical significance. In these HIV-infected young adults treated with atazanavir-ritonavir plus TDF, the atazanavir AUC was similar to those of older adults treated with the combination. Based on data for healthy volunteers, a higher tenofovir AUC may have been expected, but was not seen in these subjects. This might be due to faster tenofovir CL/F because of higher creatinine clearance in this age group. Additional studies of the exposure-response relationships of this regimen in children, adolescents, and adults would advance our knowledge of its pharmacodynamic properties.",
author = "Kiser, {Jennifer J.} and Fletcher, {Courtney V.} and Flynn, {Patricia M.} and Cunningham, {Coleen K.} and Wilson, {Craig M.} and Kapogiannis, {Bill G.} and Hanna Major-Wilson and Viani, {Rolando M.} and Liu, {Nancy X.} and Muenz, {Larry R.} and Harris, {D. Robert} and Havens, {Peter L.} and Ana Puga and Esmine Leonard and Zulma Eysallenne and Marvin Belzer and Cathy Salata and Diane Tucker and Jaime Martinez and Kelly Bojan and Rachel Jackson and Futterman, {Donna C.} and Elizabeth Enriquez-Bruce and Maria Campos and Linda Levin-Carmine and Mary Geiger and Angela Lee and Nehali Patel and Aditya Gaur and Mary Dillard and Ligia Peralta and Leonel Flores and Esther Collinetti and Lawrence Friedman and Donna Maturo and Bret Rudy and Mary Tanney and Adrienne DiBenedetto and Patricia Emmanuel and Silvia Callejas and Priscilla Julian",
year = "2008",
month = "2",
doi = "10.1128/AAC.00761-07",
language = "English (US)",
volume = "52",
pages = "631--637",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection

AU - Kiser, Jennifer J.

AU - Fletcher, Courtney V.

AU - Flynn, Patricia M.

AU - Cunningham, Coleen K.

AU - Wilson, Craig M.

AU - Kapogiannis, Bill G.

AU - Major-Wilson, Hanna

AU - Viani, Rolando M.

AU - Liu, Nancy X.

AU - Muenz, Larry R.

AU - Harris, D. Robert

AU - Havens, Peter L.

AU - Puga, Ana

AU - Leonard, Esmine

AU - Eysallenne, Zulma

AU - Belzer, Marvin

AU - Salata, Cathy

AU - Tucker, Diane

AU - Martinez, Jaime

AU - Bojan, Kelly

AU - Jackson, Rachel

AU - Futterman, Donna C.

AU - Enriquez-Bruce, Elizabeth

AU - Campos, Maria

AU - Levin-Carmine, Linda

AU - Geiger, Mary

AU - Lee, Angela

AU - Patel, Nehali

AU - Gaur, Aditya

AU - Dillard, Mary

AU - Peralta, Ligia

AU - Flores, Leonel

AU - Collinetti, Esther

AU - Friedman, Lawrence

AU - Maturo, Donna

AU - Rudy, Bret

AU - Tanney, Mary

AU - DiBenedetto, Adrienne

AU - Emmanuel, Patricia

AU - Callejas, Silvia

AU - Julian, Priscilla

PY - 2008/2

Y1 - 2008/2

N2 - The primary objective of this study was to measure atazanavir-ritonavir and tenofovir pharmacokinetics when the drugs were used in combination in young adults with human immunodeficiency virus (HIV). HIV-infected subjects ≥ 18 to < 25 years old receiving (≥28 days) 300/100 mg atazanavir-ritonavir plus 300 mg tenofovir disoproxil fumarate (TDF) plus one or more other nucleoside analogs underwent intensive 24-h pharmacokinetic studies following a light meal. Peripheral blood mononuclear cells were obtained at 1, 4, and 24 h postdose for quantification of intracellular tenofovir diphosphate (TFV-DP) concentrations. Twenty-two subjects were eligible for analyses. The geometric mean (95% confidence interval [CI]) atazanavir area under the concentration-time curve from 0 to 24 h (AUC0-24), maximum concentration of drug in serum (Cmax), concentration at 24 h postdose (C24), and total apparent oral clearance (CL/F) values were 35,971 ng · hr/ml (30,853 to 41,898), 3,504 ng/ml (2,978 to 4,105), 578 ng/ml (474 to 704), and 8.3 liter/hr (7.2 to 9.7), respectively. The geometric mean (95% CI) tenofovir AUC 0-24, Cmax, C24, and CL/F values were 2,762 ng · hr/ml (2,392 to 3,041), 254 ng/ml (221 to 292), 60 ng/ml (52 to 68), and 49.2 liter/hr (43.8 to 55.3), respectively. Body weight was significantly predictive of CL/F for all three drugs. For every 10-kg increase in weight, there was a 10%, 14.8%, and 6.8% increase in the atazanavir, ritonavir, and tenofovir CL/F, respectively (P ≤ 0.01). Renal function was predictive of tenofovir CL/F. For every 10 ml/min increase in creatinine clearance, there was a 4.6% increase in tenofovir CL/F (P < 0.0001). The geometric mean (95% CI) TFV-DP concentrations at 1, 4, and 24 h postdose were 96.4 (71.5 to 130), 93.3 (68 to 130), and 92.7 (70 to 123) fmol/million cells. There was an association between renal function, tenofovir AUC, and tenofovir Cmax and intracellular TFV-DP concentrations, although none of these associations reached statistical significance. In these HIV-infected young adults treated with atazanavir-ritonavir plus TDF, the atazanavir AUC was similar to those of older adults treated with the combination. Based on data for healthy volunteers, a higher tenofovir AUC may have been expected, but was not seen in these subjects. This might be due to faster tenofovir CL/F because of higher creatinine clearance in this age group. Additional studies of the exposure-response relationships of this regimen in children, adolescents, and adults would advance our knowledge of its pharmacodynamic properties.

AB - The primary objective of this study was to measure atazanavir-ritonavir and tenofovir pharmacokinetics when the drugs were used in combination in young adults with human immunodeficiency virus (HIV). HIV-infected subjects ≥ 18 to < 25 years old receiving (≥28 days) 300/100 mg atazanavir-ritonavir plus 300 mg tenofovir disoproxil fumarate (TDF) plus one or more other nucleoside analogs underwent intensive 24-h pharmacokinetic studies following a light meal. Peripheral blood mononuclear cells were obtained at 1, 4, and 24 h postdose for quantification of intracellular tenofovir diphosphate (TFV-DP) concentrations. Twenty-two subjects were eligible for analyses. The geometric mean (95% confidence interval [CI]) atazanavir area under the concentration-time curve from 0 to 24 h (AUC0-24), maximum concentration of drug in serum (Cmax), concentration at 24 h postdose (C24), and total apparent oral clearance (CL/F) values were 35,971 ng · hr/ml (30,853 to 41,898), 3,504 ng/ml (2,978 to 4,105), 578 ng/ml (474 to 704), and 8.3 liter/hr (7.2 to 9.7), respectively. The geometric mean (95% CI) tenofovir AUC 0-24, Cmax, C24, and CL/F values were 2,762 ng · hr/ml (2,392 to 3,041), 254 ng/ml (221 to 292), 60 ng/ml (52 to 68), and 49.2 liter/hr (43.8 to 55.3), respectively. Body weight was significantly predictive of CL/F for all three drugs. For every 10-kg increase in weight, there was a 10%, 14.8%, and 6.8% increase in the atazanavir, ritonavir, and tenofovir CL/F, respectively (P ≤ 0.01). Renal function was predictive of tenofovir CL/F. For every 10 ml/min increase in creatinine clearance, there was a 4.6% increase in tenofovir CL/F (P < 0.0001). The geometric mean (95% CI) TFV-DP concentrations at 1, 4, and 24 h postdose were 96.4 (71.5 to 130), 93.3 (68 to 130), and 92.7 (70 to 123) fmol/million cells. There was an association between renal function, tenofovir AUC, and tenofovir Cmax and intracellular TFV-DP concentrations, although none of these associations reached statistical significance. In these HIV-infected young adults treated with atazanavir-ritonavir plus TDF, the atazanavir AUC was similar to those of older adults treated with the combination. Based on data for healthy volunteers, a higher tenofovir AUC may have been expected, but was not seen in these subjects. This might be due to faster tenofovir CL/F because of higher creatinine clearance in this age group. Additional studies of the exposure-response relationships of this regimen in children, adolescents, and adults would advance our knowledge of its pharmacodynamic properties.

UR - http://www.scopus.com/inward/record.url?scp=38649116329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649116329&partnerID=8YFLogxK

U2 - 10.1128/AAC.00761-07

DO - 10.1128/AAC.00761-07

M3 - Article

VL - 52

SP - 631

EP - 637

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -